Revenue
0 USD
2026 Q2 · USD
Exact inputs and evidence
- Revenue: 0 USD Source
Fundies. English
Crescent Biopharma, Inc.
EDGARAnnual consolidated revenue for 2025: about USD 10.84M, using the latest reported figures.
Latest quarter
Operating cash flow
-19.5 million USD
2026 Q2 · USD
Free cash flow
-19.5 million USD
2026 Q2 · USD
- Cash and cash equivalents
- 172 million USD Source
Exact value
171593000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 27.8 million shares Source
Exact value
27756044 shares
Reported share-count change
99.79% · 13.9 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-15.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 1 of 11 periods available· newest 2025-12-31
- Operating income: 1 of 11 periods available· newest 2025-12-31
- Net income: 1 of 11 periods available· newest 2025-12-31
- Operating cash flow: 1 of 11 periods available· newest 2025-12-31
- Capital expenditure: 1 of 11 periods available· newest 2025-12-31
- Total assets: 1 of 11 periods available· newest 2025-12-31
- Total liabilities: 1 of 11 periods available· newest 2025-12-31
- Current assets: 1 of 11 periods available· newest 2025-12-31
- Current liabilities: 1 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 1 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 1 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
No unambiguous prior-year comparison is available for the latest reporting period.
Comparable inputs unavailable for: Revenue, Net income, Operating cash flow, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 10.84 million 100% of revenue
- Operating costs Derived USD 163.48 million 1,508% of revenue
- Operating income −USD 152.63 million −1,408% of revenue
- Tax, interest and other Derived USD 1.31 million 12% of revenue
- Net income −USD 153.94 million −1,420% of revenue
Cash
- Operating cash flow −USD 71.5 million −659% of revenue
- Capital expenditure USD 919,000 8.5% of revenue
- Free cash flow Derived −USD 72.42 million −668% of revenue
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2025 Operating loss: operating costs were 1,508% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2025 2025-01-01 – 2025-12-31 | 10844000 | 163476000 Derived | -152632000 | 1310000 Derived | -153942000 | -72419000 Derived | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 10.8M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2025 | Revenue | 10844000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -1,407.5% 2025
Net margin -1,419.6% 2025
Free cash flow margin -667.8% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025 | Operating margin | -1,407.5% |
|
| 2025 | Net margin | -1,419.6% |
|
| 2025 | Free cash flow margin | -667.8% |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -71.5M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2025 | Operating cash flow | -71500000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
USD -72.4M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2025 | Free cash flow | -72419000 |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
15.5% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025 | Liabilities / assets | 15.5% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
6.56× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025 | Current assets / current liabilities | 6.56× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2025 2025-01-01 – 2025-12-31 | −USD 153.94 million Exact valueExact value: -153942000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 71.5 million Exact valueExact value: -71500000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 919,000 Exact valueExact value: 919000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 72.42 million Calculation and evidence-71500000 − 919000 USD Exact free cash flow: -72419000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
114 filings · 4,053 latest values · 4,053 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001253689, 1253689, CBIO, GLYC, edgar:1253689
Also known as CRESCENT BIOPHARMA, INC., Crescent Biopharma, Inc., GLYCOMIMETICS INC, GLYCOMIMETICS, INC., GlycoMimetics, Inc.